Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Family Centered Care Cohort Study 1 in Nagano Children's Hospital

NCT04761419 · tracked via the Priya Life Science Japan tracker
Sponsor
Nagano Children's Hospital
Phase
Observational
Started
2021-02-01
Last updated
2026-04-13

Condition(s) studied

Family Centered Care

Investigational drug(s) / intervention(s)

Parents' longer presence beside their infant

Parents' longer presence beside their infant: They are not intervention. We will collect data about these items.

Study summary

An observational cohort study to show the effect of parents' presence beside their infants, skin-to-skin contact (SCC), participation in infant care, or any interaction with their infants on parents' and infants' short- and long-term outcomes. Investigators create a hypothesis that longer parents' presence, SCC, participation in infant care, and any interaction with their infants affect outcomes of infants and parents by preventing parents' depression and promoting parent-infant bonding and, in addition, by shortening the length of stay, promoting growth, promoting establishment breastfeeding, and improving developmental outcomes. Parents are asked to make a record of the length of their presence, SCC, participation in infant care, and any interaction with their infants, which are quantitative measurements of family centered care (FCC). Investigators also collect the data related to the background information of the family, delivery, the clinical course of infants, and the outcome measures of the infants and parents. No intervention is included in this research.

The study setting is a level IV neonatal intensive care unit (NICU) at Nagano Children's Hospital in Nagano, Japan. Eligible infants are those who are born at 34 weeks of gestation or earlier from Japanese parents in Nagano Children's Hospital and need admission into NICU in the same hospital. Infants are excluded from this study if they have any major anomalies including suspicion of chromosomal disorder on admission, if at least one parent is Not Japanese, or if they do not survive until discharge home.

The primary outcomes are the EPDS and Japanese version of Mother-to-Infant Bonding Scale (MIBS-J) of the parents. The secondary outcomes are the followings; (1) length of stay (days), (2) physical measurements at 36 weeks (g or cm) and growth rate from birth to discharge home (g or cm /d), (3) breastmilk-feeding (exclusive, partial, or no breast milk) and the frequency of breastfeeding directly from breast at 36 weeks PMA and at discharge (average frequency per day), and for the infants whose birth weight \<1500g only, (4) developmental quotient (DQ) at 6 and 18 months of corrected age, and 3 years old assessed by Kyoto Scale of Psychological Development (KSPD).

Eligibility

Sex
ALL
Min age
—
Max age
7 Days
Healthy volunteers
No
Inclusion Criteria: * Born at 34 weeks of gestation or earlier in Nagano Children's Hospital and need admission into NICU in the same hospital Exclusion Criteria: * Having any major anomalies including suspicion of chromosomal disorder on admission * At least one parent is Not Japanese * The consent is not obtained by day 7 * Do not survive until discharge home

Primary outcome measure(s)

  • The Edinburgh Postnatal Depression Scale (EPDS) of mother 1 — 2 weeks postpartum.
    Indicators to estimate depression in parents. The total score varies from minimum 0 to maximum 30, and higher scores indicates to have more depressive symptoms.
  • The Edinburgh Postnatal Depression Scale (EPDS) of mother 2 — 4 weeks postpartum.
    Indicators to estimate depression in parents. The total score varies from minimum 0 to maximum 30, and higher scores indicates to have more depressive symptoms.
  • The Edinburgh Postnatal Depression Scale (EPDS) of mother 3 — At discharge of the infant, an average of 2 months postpartum.
    Indicators to estimate depression in parents. The total score varies from minimum 0 to maximum 30, and higher scores indicates to have more depressive symptoms.
  • The Edinburgh Postnatal Depression Scale (EPDS) of father 1 — Within 1 month postpartum.
    Indicators to estimate depression in parents. The total score varies from minimum 0 to maximum 30, and higher scores indicates to have more depressive symptoms.
  • The Edinburgh Postnatal Depression Scale (EPDS) of father 2 — At discharge of the infant, an average of 2 months postpartum.
    Indicators to estimate depression in parents. The total score varies from minimum 0 to maximum 30, and higher scores indicates to have more depressive symptoms.
  • Japanese version of Mother-to-Infant Bonding Scale (MIBS-J) for mother 1 — 2 weeks postpartum.
    Indicators to estimate bonding between infant and parents. The total score varies from minimum 0 to maximum 30, and higher scores indicate a problematic bonding between a mother and her infant.
  • Japanese version of Mother-to-Infant Bonding Scale (MIBS-J) for mother 2 — 4 weeks postpartum.
    Indicators to estimate bonding between infant and parents. The total score varies from minimum 0 to maximum 30, and higher scores indicate a problematic bonding between a mother and her infant.
  • Japanese version of Mother-to-Infant Bonding Scale (MIBS-J) for mother 3 — At discharge of the infant, an average of 2 months postpartum.
    Indicators to estimate bonding between infant and parents. The total score varies from minimum 0 to maximum 30, and higher scores indicate a problematic bonding between a mother and her infant.
  • Japanese version of Mother-to-Infant Bonding Scale (MIBS-J) for father 1 — Within 1 month postpartum.
    Indicators to estimate bonding between infant and parents. The total score varies from minimum 0 to maximum 30, and higher scores indicate a problematic bonding between a mother and her infant.
  • Japanese version of Mother-to-Infant Bonding Scale (MIBS-J) for father 2 — At discharge of the infant, an average of 2 months postpartum.
    Indicators to estimate bonding between infant and parents. The total score varies from minimum 0 to maximum 30, and higher scores indicate a problematic bonding between a mother and her infant.

Trial sites (1)

FacilityCityRegionStatus
Nagano Children's Hospital Azumino Nagano

More Nagano Children's Hospital trials in Japan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04761419 on ClinicalTrials.gov ↗ ← All trials in Japan